GlycoNex, Inc. AI Stock Analysis
GlycoNex, Inc. (4168) AI Stock Analysis
GlycoNex, Inc.
(TPEx:4168)
The score is held down primarily by weak financial performance: persistent operating losses near NT$250 million per year, consistently negative operating and free cash flow, and a shrinking equity base now supplemented by NT$474 million of new borrowings, which raises funding and dilution risk. Technicals add further pressure, with the price below all major moving averages and a negative MACD, although a deeply oversold RSI hints at potential short-term stabilisation. Valuation provides no support given negative earnings and no dividend. Offsetting positives — a 335% revenue jump, gross margin expansion to 62%, and reduced cash burn — are encouraging but still early-stage, leaving the investment case dependent on pipeline progress rather than current financials.
GlycoNex, Inc. (4168) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 2.27B
- Dividend Yield
- ―
- Average Volume (3M)
- 89.93K
- Price to Earnings (P/E)
- -8.6
- Beta (1Y)
- 0.39
- Revenue Growth
- -36.49%
- EPS Growth
- -29.76%
- Country
- TW
- Employees
- 25
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
GlycoNex, Inc. Business Overview & Revenue Model
Company Description
GlycoNex Incorporation, based in New Taipei City, Taiwan, specializes in developing innovative cancer therapeutics. The company achieves this by leveraging advanced glycosphingolipid antigen and human monoclonal antibody technologies. Its robust pipe...
GlycoNex, Inc. Financial Statement Overview
Summary
GlycoNex is a clinical-stage biotech with weak fundamentals. The income statement (score 14) shows minimal, highly volatile revenue of NT$37.9 million against operating losses of roughly NT$250 million and a net margin of -621%, with no clear narrowing of losses since 2020. Cash flow (score 13) is the weakest area: operating cash flow has been negative every year, at about -NT$166 million in the latest period, and free cash flow has never been positive, leaving the company fully dependent on external funding. The balance sheet (score 45) is the relative strength, with NT$982 million of equity supporting NT$1.55 billion of assets and a manageable 0.48 debt-to-equity ratio, but equity has eroded about 36% since 2020 and borrowings jumped from near zero to NT$474 million, raising financing and dilution risk. Positives include revenue growth of 335%, gross margin expansion to 62%, and a meaningful reduction in cash burn versus the prior year.
Income Statement
14Very NegativeBalance Sheet
45NeutralCash Flow
13Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 22.21M | 37.86M | 14.70M | 2.54M | 30.09M | 5.47M |
| Gross Profit | -8.72M | 23.51M | 7.32M | 995.00K | 13.97M | 3.46M |
| EBITDA | -259.70M | -214.39M | -189.60M | -126.83M | -175.51M | -132.36M |
| Net Income | -270.39M | -235.23M | -229.71M | -178.36M | -219.82M | -172.49M |
Balance Sheet | ||||||
| Total Assets | 1.39B | 1.55B | 1.32B | 1.55B | 1.72B | 1.40B |
| Cash, Cash Equivalents and Short-Term Investments | 567.78M | 693.27M | 442.11M | 699.77M | 678.77M | 331.59M |
| Total Debt | 480.20M | 474.46M | 900.00K | 900.00K | 224.58M | 900.00K |
| Total Liabilities | 540.60M | 571.88M | 270.01M | 276.40M | 271.34M | 36.07M |
| Stockholders Equity | 850.74M | 982.35M | 1.05B | 1.28B | 1.45B | 1.36B |
Cash Flow | ||||||
| Free Cash Flow | -203.06M | -172.86M | -257.24M | -207.34M | -176.24M | -147.70M |
| Operating Cash Flow | -197.85M | -166.29M | -221.97M | -183.92M | -167.55M | -140.86M |
| Investing Cash Flow | 83.05M | 98.72M | 182.00M | 257.93M | -399.57M | 113.22M |
| Financing Cash Flow | 426.20M | 425.72M | 12.00K | -6.72M | 524.24M | -27.00K |
GlycoNex, Inc. Peers Comparison
Overall Rating
TW:827969Neutral- TW:416841Neutral
Financial Indicators
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4168 | GlycoNex, Inc. | 20.90 | -1.30 | -5.86% | |
| TW:6892 | Taiwan Bio Therapeutics Co., Ltd. | 26.00 | -3.70 | -12.46% | |
| TW:6932 | Merdury Biopharmaceutical Corporation | 5.23 | -5.02 | -48.98% | |
| TW:7731 | MARX Biotech Co., Ltd. | 4.26 | -1.08 | -20.21% | |
| TW:7860 | Teh Seng Pharmaceutical Mfg Co Ltd | 77.80 | 5.13 | 7.07% | |
| TW:8279 | Syngen Biotech Co., Ltd. | 80.90 | -43.20 | -34.81% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026